XERS SEC Filings: 8-K, 10-Q, S-3 & 424B – Xeris Biopharma

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 2, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

Nov 5, 2026

8-K

Xeris Biopharma Appoints Menassie M. Taddese to Board of Directors

Nov 2, 2026

8-K

Xeris Biopharma Files Patent Infringement Lawsuits Regarding KEVEYIS

Oct 14, 2026

8-K

Xeris Pharmaceuticals Outlines Clinical Development and Commercial Strategy for XP-8121

Sep 9, 2026

8-K

Xeris Biopharma Reports Second Quarter 2026 Financial Results and Tightens Full-Year Guidance

Aug 6, 2026

8-K

Xeris Biopharma Holdings, Inc. Completes Exchange and Conversion of All Outstanding 2028 Convertible Senior Notes

Jul 17, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

ATM | Offering amount: $75,000,000

May 11, 2022

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 15,358,362 | Warrants amount: 5,119,454

Feb 8, 2022

425

Form 425 - Prospectuses and communications, business combinations

Jul 30, 2021

424B3

UPDATED

Jul 29, 2021

425

Form 425 - Prospectuses and communications, business combinations

Jul 28, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8